Turn EHA data into business-critical insights. 30 high-prescribing hem/oncs analyze 10 Non-Hodgkin Lymphoma abstracts to help you prepare for what’s next. Take the guesswork out of understanding changes in prescribing behavior for: axicabtagene ciloleucel, epcoritamab, glofitamab, mosunetuzumab, naratuximab emtansine, pirtobrutinib (LOXO-305), polatuzumab vedotin, rituximab, and tisagenlecleucel among others. Get your 60+ slide report.

Non-Hodgkin Lymphoma Report EHA 2021

European Hematology Association

Virtual Meeting
Jun 9 to Jun 17

Share: